EyePoint Pharmaceuticals Announces U.S. Commercial Launch of DEXYCU (dexamethasone intraocular suspension) 9%

NEXT STORY
ERYTECH presenta le sue conclusioni in occasione del meeting della European Red Cell Research Society
PREV STORY
Clearside Biomedical Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

POINT Biopharma Strengthens Senior Management Team with Appointment of Dr. Myra Rosario Herrle as EVP, Regulatory Affairs

author_avatar
NASDAQ Market News

AzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

author_avatar
NASDAQ Market News

New Scientific Advisors Focused on Cell Therapy in Immuno-Oncology and Autoimmunity Join Intellia Therapeutics

CAMBRIDGE, Mass., May 14, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading ...

author_avatar
NASDAQ Market News